Population pharmacokinetics of lamotrigine

Chan, V., Morris, R. G., Ilett, K. F. and Tett, S. E. (2001) Population pharmacokinetics of lamotrigine. Therapeutic Drug Monitoring, 23 6: 630-635. doi:10.1097/00007691-200112000-00006

Author Chan, V.
Morris, R. G.
Ilett, K. F.
Tett, S. E.
Title Population pharmacokinetics of lamotrigine
Journal name Therapeutic Drug Monitoring   Check publisher's open access policy
ISSN 0163-4356
Publication date 2001-01-01
Year available 2001
Sub-type Article (original research)
DOI 10.1097/00007691-200112000-00006
Open Access Status
Volume 23
Issue 6
Start page 630
End page 635
Total pages 6
Editor S. J. Soldin
F. Sjoqvist
Place of publication Philadelphia
Publisher Lippincott & Wilkins
Language eng
Subject C1
320502 Basic Pharmacology
730199 Clinical health not specific to particular organs, diseases and conditions
Abstract The present study estimated the population pharmacokinetics of lamotrigine in patients receiving oral lamotrigine therapy with drug concentration monitoring, and determined intersubject and intrasubject variability. A total of 129 patients were analyzed from two clinical sites. Of these, 124 patients provided spare data (198 concentration-time points); nine patients (four from a previous group plus five from the current group) provided rich data (431 points). The population analysis was conducted using P-PHARM (TM) (SIMED Scientific Software, Cedex, France), a nonlinear mixed-effect modeling program. A single exponential elimination model (first-order absorption) with heteroscedastic weighting was used. Apparent clearance (CL/F) and volume of distribution (V/F) were the pharmacokinetic parameters estimated. Covariate analysis was performed to determine which factors explained any of the variability associated with lamotrigine clearance. Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg. Intersubject and intrasubject variability for clearance was 38% and 38%, respectively. The covariates of concomitant valproate and phenytoin therapy accounted for 42% of the intersubject variability of clearance. Age, gender, clinic site, and other concomitant antiepileptic drugs did not influence clearance. This study of the population pharmacokinetics of lamotrigine in patients using the drug clinically provides useful data and should lead to better dosage individualization for lamotrigine.
Keyword Medical Laboratory Technology
Pharmacology & Pharmacy
Population Pharmacokinetics
Antiepileptic Drugs
Epileptic Patients
Q-Index Code C1
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Pharmacy Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 34 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 45 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 01:51:19 EST